Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Kintor Pharmaceutical Ltd ( (HK:9939) ) is now available.
Kintor Pharmaceutical Limited announced that the Phase II stage of its pivotal clinical trial for KX-826 tincture 1.0% has achieved its primary endpoint for treating male adult androgenetic alopecia (AGA) in China. The trial demonstrated statistically significant efficacy and safety, with both 0.5% and 1.0% BID groups showing meaningful improvements in hair growth compared to the placebo group. The Independent Data Monitoring Committee recommended continuing to the Phase III stage without modifications, indicating positive implications for Kintor’s market positioning and potential future offerings.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a pharmaceutical company incorporated in the Cayman Islands, focused on developing innovative treatments for various medical conditions. The company is engaged in the research and development of novel drugs, with a particular emphasis on treatments for androgenetic alopecia (AGA) and other dermatological conditions.
Average Trading Volume: 4,389,997
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.09B
For an in-depth examination of 9939 stock, go to TipRanks’ Overview page.